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Abstract 
In the Republic of South Africa codeine containing medicines are either sold as prescription 
only medicines or over the counter depending on the strength of codeine contained in the 
medicine. The analgesic properties of codeine are thought to be derived from the conversion 
of codeine to morphine. Codeine is often combined with nonsteroidal anti-inflammatory 
drugs (NSAIDs).Codeine is a relatively weak opioid analgesic that has seemingly addictive 
properties; the misuse of codeine-containing-medicines can cause morbidity in patients with 
known codeine addiction. The Regulation of codeine has been reviewed in a number of 
countries to try and curb the misuse of the product. This involves the reduction in the strength 
of codeine, reduction in the package size and duration of treatment of over-the-counter (OTC) 
codeine containing products and in some countries the OTC codeine containing products 
have been rescheduled into prescription only medicines.  
The study aims to monitor and describe trends in the sales of OTC codeine-containing 
medicines from Pick n Pay retail pharmacies in Gauteng, Western Cape and KwaZulu Natal 
provinces of South Africa from July 2011 to June 2014.  Secondary data on the sales of OTC 
codeine-containing medicines from Pick n Pay Pharmacies database was obtained, which 
described the(1) pharmacy name, (2) the trade name of the medicine items sold, (3) the 
quantities of the medicines sold, (4) the purchase date of medicine, (5) the cost of the 
medicine, (6) the age of the purchaser, (7) the gender of the purchaser and (8) the mode of 
payment used when purchasing for the study period. A statistical software system, SPSS® 
version 20 was used to analyse the data.  
 
The study findings indicate a steady increase in the sales of the OTC codeine containing 
medicine over the years. Females were found to be the main purchasers of these products and 
the age group which purchased most of the products is the 40 to 45 years age group. The top 
three selling brands of the OTC codeine containing medicines were found to be Genpayne 
Capsules (30%), Myprodol Capsules (27%) and Mybuline Tablets (14%) of all the sales of 
these products in the three provinces combined. The mode of payment used for these 
purchases was mainly cash payment which accounted for sixty-five percent of the payments. 
There is a need to review the Codeine Car Initiative to monitor and audit the sales of these 
products so as to make an informed decision on their appropriate regulation.  
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Chapter 1: Introduction and Background Information 
 
In the Republic of South Africa codeine containing medicines are either sold over-the-counter 
or as prescription only medicines depending on their schedule. Scheduling is a classification 
system for controlling how medicines and related chemicals are made available to the public. 
The primary consideration in scheduling a substance is its safety profile in relation to the 
therapeutic indication for its use. A medical substance may also be listed in more than one 
schedule based on its dosage form, route of administration, strength, indication, dose and 
treatment duration. The major determining factors in the scheduling of medicines in South 
Africa are the toxicity evidence of the substance, its safety in use, the proposed indication for 
the substance, the need for a medical diagnosis, monitoring, medical management by 
healthcare professionals, the abuse potential and the need for access to the substance
1
,
2
.  
 
Different countries have different pharmaceutical scheduling arrangements; Australia and 
New Zealand have four schedules which are prescription only (schedule 4), pharmacist only 
(schedule 3), pharmacy only (schedule 2) and general sale medicines. The United Kingdom 
has three schedules which are prescription only, pharmacy only and general sales medicines 
whilst the United States of America have two schedules which are prescription and non-
prescription medicines. Canada has scheduled its medicines into four schedules at provincial 
level; prescription medicines (schedule 1), pharmacist assisted (schedule 2), pharmacy self-
selection (schedule 3) and general sales
3
. South Africa has scheduled medicines into eight (8) 
schedules which can be broken down into four main schedules like Australia and New 
Zealand, and these are prescription only (schedule 3 to 8), pharmacist assisted (schedule 2), 
pharmacy only (schedule 1) and general sales (schedule 0). Internationally, a number of 
factors drive the rescheduling of medicines; in the United Kingdom, factors driving the 
rescheduling of medicines from prescription only to pharmacy only medicines include patient 
empowerment, consumerism, decreasing power of the professions, pharmacists drive to 
extend their role and the government’s policy to contain the National Health System’s 
medicine expenditure
4
. The increased public access due to the availability of non-prescription 
medicines which were previously prescription only has given rise to an increase in the trend 
of self-medication
5
,
6
.  
 
MSc [MED] Pharmaceutical Affairs – Research Protocol – PACY 2075                                                        
 
11 
In South Africa codeine phosphate is a schedule six (6) medicine but it became a schedule 
two (2) medicine when in combination with one or more therapeutically active substance(s) 
containing 20mg or less per dosage unit and for liquids oral preparations containing 20mg or 
less per 5ml dosage unit. In February 2015, the Medicines Control Council resolved to 
reschedule Acetyldihydrocodeine, Codeine, Dihydrocodeine and Norcodeine. For all 
schedule 2 listing the maximum amount of codeine and dihydrocodeine per dosage unit was 
reduced from 20mg to 10mg, the maximum daily dose was limited to 80mg and the 
maximum treatment period was reduced to five (5) days for oral solid preparations. For oral 
liquid preparations the maximum amount of codeine and dihydrocodeine per 5ml dosage unit 
was reduced from 20mg to 10mg, the maximum daily dose was limited to 80mg and the 
maximum pack size was reduced to 100ml. Codeine and dihydrocodeine oral and liquid 
preparations exceeding the maximum quantity of active per dosage unit (of 10mg) was 
included in the schedule 3 listing. Acetyldihydrocodeine and norcodeine were rescheduled 
from schedule 2 to schedule 6
7
.   
 
In Australia the National Drugs and Poisons Schedule Committee (NDPSC) in June 2008 
formed a Codeine Working Party to review the availability of all over-the-counter (OTC) 
combination analgesics containing codeine following concerns on the abuse of codeine-
ibuprofen combination analgesic products. In February 2009 the NDPSC; based on the report 
from the Codeine Working Party decided not to reschedule all OTC codeine from Schedule 2 
to Schedule 3 but decided to limit the maximum daily dose to 100mg codeine, limit the pack 
size to a five (5) days’ supply, restrict preparations to 12mg of codeine per dosage unit and 
restrict undivided preparations to 0.25% codeine. In June 2009 the NDPSC agreed on the 
scheduling of OTC codeine combinations for coughs and cold to remain as they are and to 
reschedule all OTC combination analgesics containing codeine from schedule 2 to schedule 3 
with the February 2009 limits. This decision was to be implemented on the 1
st
 of May 2010
8
.  
 
The rescheduling of codeine to schedule 3 in Australia failed to achieve the required 
reduction in harm to affected individuals. Further studies indicated no reduction in the risk 
associated with codeine since the rescheduling in the year 2010. Codeine is increasingly a 
drug of abuse in Australia with some individuals developing severe adverse effects from the 
high doses of paracetamol and ibuprofen that accompany the use of large numbers of tablets 
in codeine-dependent persons.  An interim decision was made by the Australian Advisory 
Committee on Medicines Scheduling to be implemented on the 1
st
 of June 2016 to delete the 
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schedule 3 entry for codeine and reschedule all current schedule 3 codeine to schedule 4  
(prescription only) as a result of issues of morbidity, toxicity and dependence
8
. In Europe, 
codeine is not an OTC medicine; codeine is a prescription only medicine in thirteen (13) 
countries in Europe namely; Austria, Belgium, Croatia, Czech Republic, Finland, Germany, 
Greece, Italy, Luxembourg, Portugal, Slovakia, Spain and Sweden. Codeine is also a 
prescription only medicine in the USA, Hong Kong, Iceland, India, Japan, Maldives, 
Romania, Russia and the United Arab Emirates
8
,  
 
Codeine and dihydrocodeine are contained in many medicines sold over-the-counter in the 
United Kingdom pharmacies. In July 2005, a voluntary agreement was reached with 
manufacturers to restrict the pack sizes of OTC medicines containing codeine or 
dihydrocodeine to 32 tablets. In January 2009 the All-Party Parliamentary Drug Misuse 
Group (APPDMG) published a report with evidence received from the Royal Pharmaceutical 
Society of Great Britain, the self-help group over-count and the Medicines and Healthcare 
products Regulatory Agency (MHRA) on physical dependence and addiction to prescription 
and OTC medicines. The APPDMG made recommendations to reduce the risk of misuse of 
medicines in particular OTC medicines containing codeine or dihydrocodeine on the basis of 
the information from the report, the new sales data and information from the self-help group. 
The recommendations stated that all indications relating to colds, influenza, coughs and sore 
throat and reference to minor pain conditions should be removed from product information; 
the patient information leaflets and labels should state that the products are for short-term use 
only; all pack sizes greater than 32 tablets of solid dose codeine or dihydrocodeine-containing 
OTC medicines including effervescent formulations will only be available on prescription 
only and advertisements should be updated to reflect the new indications and warnings 
without making reference to the painkilling power and strength and the advert should include 
the statement, “can cause addiction and for three days use only”9.  
 
Addiction has traditionally been associated with illicit substance abuse. However, an 
increasing number of cases are being associated with the intake of codeine, although 
considered a weak opioid, codeine, like all opioids is associated with tolerance and 
dependence with long term use. In clinical use, codeine is mainly used as an analgesic, an 
antidiarrheal and or a cough suppressant agent
 10
. However, there is no evidence suggesting 
that codeine shortens the duration or reduces the severity of paediatric coughs
11
. The 
analgesic properties of codeine are thought to be derived from the conversion of codeine to 
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morphine. Codeine, also known as 3-methylmorphine is a pro-drug and as such it has to be 
converted to morphine for it to be active and this is achieved through the removal of a methyl 
group by the cytochrome P4502D6 enzyme
12
. The known analgesic efficacy of codeine is 
influenced by the polymorphisms of the cytochrome P450 enzymes
13
. There is significant 
inter-individual variability in the activity of this enzyme and the generic variations affect the 
rate at which people convert the prodrug to morphine. 
 
An in-vitro DNA sequence variation at a single location in the genome resulting in two allelic 
variants is called a single nucleotide polymorphism (SNP) occurring commonly within a 
population. This occurrence implies that the distributions among populations of the variant 
forms can differ but overall, they are consistent with a population. The CYP2D6 (a 
Cytochrome P450 2D6 enzyme in humans) has an important role in the metabolism of about 
twenty-five (25) percent of currently used medicines; these include many agents used to treat 
pain. Therefore, the presence of an allelic variant in a particular CYP isoform will result in 
one of four drug-metabolizing phenotypes namely; poor metabolizers, intermediate 
metabolizers, extensive metabolizers or ultra-rapid metabolizers
14’15.   
 
So far, only about ten per cent (10%) of the codeine dose is converted to morphine and other 
metabolites such as norcodeine, normorphine and hydrocodone. Codeine and its metabolites 
are excreted by the kidney as conjugates with glucoronic acid
16
.  Common adverse effects 
associated with the use of codeine are drowsiness and constipation, less common adverse 
effects include itching, nausea, vomiting, dry mouth, miosis, orthostatic hypotension, urinary 
retention, depression, and coughing. Rare adverse effects include anaphylaxis, seizure, acute 
pancreatitis and respiratory depression
17
. Individuals with poor metabolizer phenotype tend to 
have virtually undetectable levels of morphine as a result codeine lacks efficacy in this 
group
18
.  However, ultra-rapid metabolizers’ phenotypes individuals will extensively 
metabolize codeine to morphine increasing the risk of respiratory depression at regular doses 
of codeine
19
.  This is exacerbated by higher and or repeated doses of codeine.  
 
Pharmacogenetic variants of codeine have been identified which can influence the rate at 
which codeine is metabolised to morphine and its subsequent effects. The global distribution 
of ultrafast metabolising variant of CYP2DP varies geographically (40% in North Africa, 
26% in Oceania, 12% in the Middle East, 8% in North America and 3% in Europe), and this 
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results in the production of high levels of morphine after codeine intake
20
.  Pharmacogenetics 
is the study of inherited genetic differences in medicine metabolic pathways affecting the 
individual’s therapeutic response and adverse effects to medicines21. The pharmacokinetics of 
codeine is unpredictable. Codeine has been used for over two hundred (200) years; but it has 
not been subjected to the mandatory vigorous safety studies applied to new chemical entities. 
 
Limited research has been done on the extent and the nature of the over-the-counter (OTC) 
medicine misuse in South Africa. The findings from the specialist treatment centres in Cape 
Town indicated that Benzodiazepines are the most misused products followed by analgesics. 
The study indicated that of the misused analgesics the codeine-containing OTC medicines 
were the ones mostly misused. The study highlighted that patients using OTC medicines as 
their primary drug of misuse are more likely to be females aged over forty (40) years whilst 
males over the age of forty (40) use OTC medicines as an additional drug of misuse
22
. Deaths 
and serious morbidity such as liver toxicity and gastric haemorrhage have been reported. 
Codeine dependence and abuse have been reported to occur in people who have used OTC 
products for pain conditions initially.  
 
Over-the-counter medicines are generally medicines of acceptable safety margin, low misuse 
and abuse potential. They are medicines where a medical practitioner is not needed for the 
safe and effective use of the product since they are easy to recognize and use
23
. The 
availability of medicines without a prescription from a medical practitioner has offered 
benefits in terms of improved access, choice of medicines, the involvement of individuals in 
their health and in the decision making process thus reducing healthcare costs
 24
.  It has been 
suggested that the low price of codeine containing medicines, their ease of availability over-
the-counter and the tendency of the public to perceive OTC medicines to be safer than the 
prescription medicines contribute a lot to their rapidly increasing potential as drugs of abuse
 
25, 26, 27, 28
.  
 
Similarly, codeine can be used as a recreational drug and the potential of codeine abuse is 
lower than that of heroin or morphine. However, the ingestion of large doses of codeine 
produce euphoric effects, thus illicit opioid users turn to these non-prescription products in 
the absence of their usual opioid supplies
29
.  A heroin addict may use codeine to ward off the 
the unpleasant physical reaction that accompanies the process of ceasing to take an addictive 
drug such as heroin. The misuse of codeine-containing-medicines can cause morbidity in 
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patients with known codeine addiction
30,31
.  According to Matthew F. et al study findings, 
96% of the patients in the study reporting prolonged use of high doses of OTC medicines 
containing codeine and ibuprofen exhibited non-steroidal anti-inflammatory drug (NSAID) 
toxicity which included gastrointestinal diseases, renal failure, anaemia and severe 
hypokalaemia.  
 
Analgesics with anti-inflammatory properties as a group of pharmaceuticals record the 
highest sales among OTC medicines
32
. A large proportion of OTC analgesics contain 
NSAIDs in combination with other agents such as codeine and paracetamol
33
 in varying 
concentrations.  There is limited evidence to suggest the analgesic benefits caused by the 
synergy obtained from the incorporation of low-dose codeine into combination analgesics
34
. 
There are disadvantages however, in combining relatively safe analgesics like ibuprofen and 
paracetamol with small doses of opioids that may bring about minimal therapeutic benefits 
but increase the risk profile of the medicines in terms of abuse, addiction and adverse 
effects
35
. If high doses of combination analgesics are ingested in a bid to experience the 
opioid effects, there is an increased likelihood of the occurrence of non-opioid toxicity as a 
result of the other combination analgesic such as ibuprofen, aspirin or paracetamol in the 
preparation
 36
. The misuse of these products may indicate that patients lack knowledge on the 
potential side effects associated with their medication especially OTC medicines. 
 
The combinations of codeine with ibuprofen and combinations of codeine with paracetamol 
have been observed to be problematic largely because ibuprofen has been said to cause 
perforated gastric ulcers and hypokalaemia secondary to renal acidosis
 37, 38, 39, 40, 41
. Although 
paracetamol does not cause gastrointestinal problems like ibuprofen, it can cause liver 
damage when large doses are ingested per given time. Paracetamol is metabolized in the liver 
and if the liver glutathione is depleted, hepatotoxicity may occur.  
The United States Food and Drug Authority (US-FDA), European Medicine Agency (EMA) 
and the Agenzia Italiana del Farmaco (AIFA) confirmed a ban on the use of codeine in 
children undergoing surgery for tonsillectomy and adenoidectomy for obstructive sleep 
apnea. EMA and AIFA extended this ban on the use of codeine used for pain control in 
children under twelve (12) years
42
. Codeine has a high potential for abuse and addiction, but 
the US-FDA panel was more worried about children suffering dangerous side effects than 
children becoming addicted. The US-FDA has been updating codeine’s warnings for almost a 
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decade. In 2007, the agency added a statement about a risk of respiratory depression in 
infants and nursing mothers to the label of drugs containing codeine. In 2012, the agency 
announced it had received reports of children dying after taking codeine following a 
tonsillectomy or an adenoidectomy.  Then in 2013, the agency issued a black-box warning, 
its strongest warning, about the risk of death in children who receive codeine after a 
tonsillectomy or adenoidectomy
43
. In South Africa, patients are required to supply key 
personal details such as name, date of birth and address, when purchasing a range of popular 
OTC medicines containing codeine as of January 2014 however, this only happens in limited 
retail pharmacies.  
 
1.1 Rationale  
South Africa’s total expenditure on health as a percentage of GDP is 8.5 and the total 
expenditure on health per capita is 942; yet the country has poor health status indicators 
compared to other middle-income countries, despite such high expenditure on healthcare. 
Health Care in South Africa is generally financed through a combination of mechanisms. In 
2005, allocations from general tax accounted for about forty percent (40%), whereas private 
medical schemes accounted for forty-five percent (45%), and out-of-pocket payments about 
fourteen percent (14%) of total health care financing
44; 45
.  
 
A number of countries including the United Kingdom have seen an increase in codeine 
related mortality
46
 and in the United States of America
47
, the United Kingdom and Australia
48
 
case series of codeine deaths have been reported. A potential driver of the deaths in Australia 
may have been the introduction of OTC products containing larger amounts of codeine 
including codeine combined with ibuprofen.  The stakeholders in both the South African 
Pharmaceutical Manufacturing Industry and the South African retail pharmacy have 
expressed concerns that the move to up-schedule codeine containing OTC products would put 
these medicines out of reach of many poor and economically disadvantaged South Africans.  
 
Instead, both the South African Pharmaceutical Manufacturing Industry and Retail Pharmacy 
Associations feel that effective self-regulation will help preserve the OTC sales of these 
medicines that would continue benefiting the patients.  This argument resulted in the 
initiation of the Codeine Care Initiative by the Community Pharmacist Sector (CPS) and 
MSc [MED] Pharmaceutical Affairs – Research Protocol – PACY 2075                                                        
 
17 
Pharmaceutical Society of South Africa (PSSA) to monitor and audit the sale and supply of 
codeine-containing medicines
49
. This initiative utilises the computerised system for 
monitoring sales of codeine-containing medicines. However, there were challenges with this 
initiative which included the fact that consumers had a choice of whether to participate or not,  
also it was  voluntary for pharmacies to sign up to use this initiative to access and  share their 
database and many pharmacies lacked the required software. This resulted in few retail 
pharmacies taking part in the initiative.  
 
The purpose of the research study is to establish the extent of the sales of OTC codeine-
containing medicines in retail pharmacies in South Africa. The study utilized the Pick n Pay 
Retail Chain Pharmacies database of the sales of OTC codeine-containing medicines within 
the Gauteng, Western Cape and KwaZulu Natal province as a proxy for retail pharmacies in 
South Africa.  The information may be used to inform decision-making with regards to the 
regulation and control of the sale of OTC codeine-containing products in South Africa. 
Ascertaining the trends of the sales of OTC codeine containing medicines within these 
pharmacies will also provide a basis for future studies. 
 
1.2 Research Question 
What were the trends in the sale of the OTC codeine-containing medicines in South Africa 
over the period of July 2011 to June 2014?  
 
1.3 Purpose of the study  
The purpose of the study is to monitor and describe trends in the sales of OTC codeine-
containing medicines from Pick n Pay retail pharmacies in the Gauteng Province, Western 
Cape Province and the Kwa-Zulu Natal Province over the period of July 2011 to June 2014. 
 
1.4 Specific Objectives 
The study aims to: 
 i) Describe the sales trends of OTC codeine-containing medicines; and 
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 ii) Determine the demographics of the populations purchasing OTC codeine-containing 
medicines over the study period. 
 
Chapter 2: Study Methodology 
2.1 Study Design 
This is a retrospective, descriptive study of the sales of OTC codeine-containing medicines 
using secondary date from the Pick n Pay Retail Chain Pharmacies in the Gauteng Province, 
Western Cape Province and the Kwa-Zulu Natal Province over the period of July 2011 to 
June 2014 as a proxy for retail pharmacies in South Africa. The study was a record review 
and consent from patients was not required. The Pick n Pay Retail Pharmacies were chosen 
because they are one of the retail chain pharmacies that adopted the Codeine Care Initiative 
to monitor and audit the sales and supply of codeine-containing medicines. They utilise the 
computerised system for monitoring sales of codeine-containing medicines which stand-alone 
owned pharmacies did not voluntarily sign up to use because they lacked the required 
software. The three provinces were included in the study because they have high populations 
compared to the other provinces in South Africa, together they account for more than 50% of 
the total population; the Gauteng Province has the most population followed by the Kwa-
Zulu Natal Province and lastly the Western Cape Provinces according to the 2011 census. 
Western Cape was chosen because it had more Pick n Pay pharmacies compared to the 
Eastern Cape which happens to have a high population compered to it. 
 
2.2 Study Population and Data Source 
 
Data on the sale of OTC codeine-containing medicines from eighteen (18) Pick n Pay retail 
pharmacies was extracted from twenty-five (25) Pick n Pay retail pharmacies in the three (3) 
provinces of South Africa namely; the Gauteng Province, Western Cape Province and Kwa-
Zulu Natal Province data base. The three provinces were included in the study because they 
have the highest population compared to the other provinces in South Africa. 
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2.3 Sample Size 
 
The data of the OTC codeine-containing medicines from the eighteen (18) Pick n Pay Retail 
Pharmacies in Gauteng, Western Cape and Kwa-Zulu Natal were used from the total of   
twenty-five (25) Pick n Pay retail pharmacies in the three provinces due to data availability. 
The Pick n Pay Retail Pharmacy outlets studied are shown in Table 2.3.1 below. 
 
Table 2.3.1: Pick n Pay Retail Pharmacies in the three provinces of SA that provided a sample 
for the study 
 
Site Identified Number of Pick n 
Pay Retail 
Pharmacies Studied 
% Retail Pharmacies  Population Size 
(2011 Census) 
Gauteng Province 10 55.5 12272263 
Western Cape 
Province 
5 27.8 5822734 
Kwa-Zulu Natal 3 16.7 10267306 
TOTAL  18 100 28362303 
 
2.4 Data Collection Tools and Techniques 
The data was collated using Microsoft Excel spreadsheet as a data abstraction form. 
 
Variables in the Study: 
The variables in this research study consisted of the following demographic characteristics:  
i). the pharmacy name,  
ii). the trade name of the medicine items sold,  
iii). the quantities of the medicines sold, 
iv). the purchase date of medicine, 
v). the cost of the medicine, 
vi). the age of the purchaser,  
vii). the gender of the purchaser and 
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viii). the mode of payment used when purchasing (cash or medical aid)  for the period July 
2011 to June 2014. 
 
2.5 Data Analysis 
 
A statistical software system, SPSS version 20 was used to analyse the data. Descriptive 
statistics were used to show the study results per variable and frequency distribution analyses 
were drawn.  For visual presentation of results, Microsoft Excel 2010 was used to create 
charts and graphs. Data was analysed and disaggregated by province as well as by the year in 
which sale of OTC codeine-containing medicines were made in order to see the sales trends. 
Further disaggregation of results was made in terms of other demographic variables included 
in the study such as gender, age and mode of payment. To measure the significant changes 
noted in the sampling procedure the Chi-Squire Test was applied to the relevant variables. 
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Chapter 3: Results 
 
3.1 General Demographic Information 
 
The results of the tree diagram indicates that a majority (44.1%) of the purchases of OTC 
codeine-containing medicines were made in the Gauteng Province, followed by the Western 
Cape at 32.3 % and Kwa-Zulu Natal Province accounting for 23.6% of the purchases made. 
This is in-line with the number of retail pharmacies sampled from the respective provinces 
however; it is not in line with the population sizes of the three provinces. The Gauteng 
Province has the most population followed by the Kwa-Zulu Natal Province and lastly the 
Western Cape Provinces according to the 2011 census. In order to measure if these different 
sample sizes included in the study caused any significant variations in the analysis, the Chi-
Square (X
2
) Test statistic was applied. Since the P-value is less than 0.05, the results of the 
Chi-Square show that there are significant differences noted across the provinces. The higher 
the number of pharmacies sampled in a province, the higher the number of sales irrespective 
of the population size which might have been expected to have an influence in the observed 
sales trends. 
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Figure 3.1.1: Tree Diagram Indicating the Percentage Sales of Codeine-Containing Medicine by 
Province 
 
The gender distribution of the purchasers of the codeine-containing medicines during the 
study period July 2011 to June 2014 indicates that the more purchasers of these medicines are 
females which accounts for fifty-nine (59) percent of all the purchasers in all the three 
provinces combined. The breakdown of the gender distribution over the years indicates that 
the pattern remains the same over the years with the females carrying out the most purchases 
over the provinces and over the years July 2011 to June 2014.  
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Figure 3.1.2: Gender Distribution of Codeine-Containing Medicine Purchasers per Province 
over the Years 2011 – 2014 
 
 
Figure 3.1.3: Distribution of Purchasers by Age Groups over the Study Period, July 2011 – June 
2014 
 
Figure 3.1.3 indicates the age groups distibution of the purchasers of the codeine-containig 
medicines over the study period of July 2011 to June 2014; the age group 41 to 45 years 
recorded 47.26 % of all the purchases followed by the age group of 60 plus years which 
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recorde 9.4% of all the purchase. The age group to record the least purchases over the study 
period was the age group 16 to 20 years which accounted for 1.37% of all the purchases. 
 
3.2 Retail Pharmacy Sales 
 
Table 3.2.1: Retail Pharmacy Sales of OTC Codeine-Containing Medicines per Province Cross 
Retail 
Pharmacy 
Name 
# of OTC codeine containing medicine sales Total # of 
OTC codeine 
containing 
medicine sales 
Percentage of 
Sales per retail 
pharmacy 
Western Cape 
 
KZN 
 
Gauteng 
 
Brackenfell 9361 - - 9361 8% 
Ottery 10062 - - 10062 9% 
Promenade 6952 - - 6952 6% 
Somerset Mall 6005 - - 6005 5% 
Tablet View 3548 - - 3548 3% 
Durban North - 22020 - 22020 20% 
Newcastle - 2656 - 2656 2% 
Pavilion - 1594 - 1594 1% 
Centurion - - 6249 6249 6% 
Hurlingam - - 6582 6582 6% 
Greenstone - - 5614 5614 5% 
Lone Hill - - 2689 2689 2% 
Norwood - - 8226 8226 7% 
South Gate - - 4215 4215 4% 
The Falls - - 3602 3602 3% 
Woodmead - - 2913 2913 3% 
Key West - - 2560 2560 2% 
Soweto - - 6485 6485 6% 
Total # of 
Sales 
35928 26270 49135 111333  
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The breakdown of sales over the study years by pharmacy indicates that most sales of OTC 
codeine-containing medicines were recorded by the Durban North Pharmacy in the Kwa-Zulu 
Natal Province which recorded twenty (20) percent of the total sales of all eighteen (18) retail 
pharmacies studied. This was followed by the Ottery Pharmacy in the Western Cape Province 
which recorder nine (9) percent of the sales and Brackenfell Pharmacy also in the Western 
Cape Province which recorder eight (8) percent of the sales. The pharmacy with the least 
sales of codeine-containing medicines was the Pavilion Pharmacy in the Kwa-Zulu Natal 
Province. 
 
 
 
Figure 3.2.1: Percentage Distribution of the Top Ten Selling Brands of Codeine-Containing 
Medicine in All Three Provinces, July 2011 - June 2014 
 
Figure 3.2.1 indicates that over the study period July 2011 to June 2014 the most sales by 
brand name of the OTC codeine containing medicines in all the three provinces combined 
were those of Genpayne Capsules which recorded 30% of all the sales followed by Myprodol 
Capsules which recorded 27% of all the sales and Mybulen Tablets with fourteen (14%) of all 
the sales. The top three selling brands alone accounted for 71% of all the OTC codeine-
containing medicine sales over the study period. 
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3.3 Mode of Payment of Purchasers 
 
Table 3.3.1: Mode of Payment used when Purchasing Codeine-Containing Medicine over the 
study period 
 
 Frequency Percentage Valid 
Percentage 
Cumulative 
Percentage 
 Medical 
Aid 
39511 35.49 35% 35 
Cash 71822 64.51 65% 100.0 
Total 111333 100.0 100%  
 
A majority of codeine-containing medicines purchasers (65%) use cash to pay for their 
medicines, as shown in table 3.3.1 above. The remaining 35% of the purchasers in the study 
use medical aid to pay for their medicines. 
3.4 Costs of Medicines 
 
 
Figure 3.4.1: Total Cost to Purchasers of All Codeine-Containing Medicine over the Years 
 
Figure 3.4.1 indicates that the total cost of all the codeine containing medicines purchased 
over the study period July 2011 to June 2014 was R4, 747,088.91.  
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Figure 3.4.2: Total Cost of Codeine-Containing Medicine to Purchasers Forecasted up to 2016 
 
Figure 3.4.2 above attempts to show the trends in the cost of these medicines in the event that 
the full years are represented using an extrapolation. This indicates an increase in the total 
cost spent by purchasers on the codeine containing medicines over the years in all three 
provinces. 
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Chapter 4: Provincial Analysis 
 
4.1 Gauteng Province 
 
In the Gauteng Province the top three selling OTC codeine-containing medicinal products by 
brand name are Myprodol Capsules accounting for 30% of all the sales followed by 
Genpayne Capsules accounting for 19% and lastly Mybulen Tablets accounting for 9% of all 
the sales. The top three selling brands alone accounted for 58% of all the OTC codeine-
containing medicine sales whilst the top ten selling brands accounted for 85% of all the sales 
of OTC codeine containing medicines sold in the Gauteng Province over the study period. 
 
 
Figure 4.1.1: Percentage Distribution of the Top Ten Selling Brands of Codeine-Containing 
Medicine in Gauteng Province – July 2011 – June 2014 
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Figure 4.1.2: Percentage Sales of Codeine-Containing Medicines by Mode of Payment, July 2011 
- June 2014 in the Gauteng Province 
 
Most of the purchases of codeine containing medicines were paid for using cash in the 
Gauteng Province over the study period as indicated by Figure 4.1.2. This figure indicates a 
slight decline in the cash payments and a corresponding increase in the medical Aid 
payments. 
 
4.2 Western Cape Province 
 
In the Western Cape Province the top three selling OTC codeine-containing medicinal 
products by brand name are Genpayne Capsules accounting for 28% of all the sales followed 
by Myprodol Capsules accounting for 24% and lastly Mybulen Tablets accounting for 17.5% 
of all the sales. The top three selling brands alone accounted for 70% of all the OTC codeine-
containing medicine sales whilst the top ten selling brands accounted for 90% of all the sales 
of OTC codeine containing medicines sold in the Western Province over the study period. 
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Figure 4.2.1: Percentage Distribution of the Top Ten Selling Brands of Codeine-Containing 
Medicine in Western Cape Province – July 201 – June 2014  
 
 
 
Figure 4.2.2: Percentage Sales of Codeine-Containing Medicines by Mode of Payment, July 2011 
- June 2014 in the Western Cape Province 
 
Most of the purchases of the codeine containing medicines were paid for using cash in the 
Western Cape Province over the study period as indicated by Figure 4.2.2. However, this 
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figure indicates a slight decline in the cash payments and a corresponding increase in the 
medical aid payments. 
 
4.3 Kwa-Zulu Natal Province 
 
In the Kwa-Zulu Natal Province the top three selling OTC codeine-containing medicinal 
products by brand name are Genpayne Capsules accounting for 37% of all the sales followed 
by Myprodol Capsules accounting for 29% and lastly Mybulen Tablets accounting for 15% 
of all the sales. The top three selling brands alone accounted for 81% of all the OTC codeine-
containing medicine sales whilst the top ten selling brands accounted for 93% of all the sales 
of OTC codeine containing medicines sold in the Kwa-Zulu Natal Province over the study 
period. 
 
 
Figure 4.3.1: Percentage Distribution of the Top Ten Selling Brands of Codeine-Containing 
Medicine in Kwa-Zulu Natal – July 2011 – June 2014 
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Figure 4.3.2: Percentage Sales of Codeine-Containing Medicines by Mode of Payment, July 2011 
- June 2014 in Kwa-Zulu Natal 
 
Most of the purchases of codeine containing medicines were paid for using cash in Kwa-Zulu 
Natal Province over the study period as indicated by Figure 4.3.2. However, this figure 
indicates a decline in the cash payments and a corresponding increase in the medical aid 
payments. 
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Chapter 5: Discussion 
 
There is a tendency for more products to be made available without prescriptions in countries 
that have schedules with pharmacy involvement like South Africa, Australia, New Zealand, 
Canada, France and the United Kingdom and a tendency for preparations to be held under 
prescription only schedules in the United States of America where pharmacy involvement or 
pharmacy-only schedules do not exist
3
.  According to the International Narcotics Control 
Board Report of 2010 on the availability of internationally controlled drugs, South Africa is 
ranked number one in Africa and number 49 in the world (of 193 countries) in terms of 
average consumption of defined daily doses of narcotic drugs
50
. South Africa is a signatory to 
three major conventions and the International Narcotics Control Board (INCB) calls upon all 
governments to be vigilant for problems involving the abuse of pharmaceutical preparations 
not requiring prescriptions and adopt measured to effectively prevent the abuse of these 
preparations.  
 
The study used the Pick n Pay retail pharmacies sales from Gauteng Province, Kwa-Zulu 
Natal Province and   the Western Cape Province as a proxy for retail pharmacies in South 
Africa. The total sales of OTC codeine containing medicines within the eighteen pharmacies 
studied during the study period accounted for four million seven hundred and forty seven 
thousand and eighty-eight Rands ninety-one cents (R4, 747,088.91).  Sixty-five (65%) 
percent of the purchases were paid for using cash payment and the medical aid payments 
accounted for thirty-five (35%) percent This means that three million and eighty five 
thousand six hundred and seven Rands seventy-nine cents  (R3,085,607.79) accounted for 
cash payments for these OTC codeine containing medicines purchases which translates to out 
of pocket expenditure. Another study has shown that the main cost drivers of medical 
schemes expenditure are private hospitals, specialists and medicines
51
. Once an individual 
has exhausted the fund allocated to medicines within their medical aid or purchases any 
medicines not covered by the medical aid then they have to pay for their medicines out of 
pocket
52
.  
 
The cash payments for the purchases of codeine containing medicine per province accounted 
for fifty-nine (59%) percent of payments in the Gauteng Province, sixty-one (61%) percent of 
all the payments in the Western Cape Province and sixty-six (66%) percent of all the 
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payments in the Kwa-Zulu Natal Province. The results indicate that Gauteng Province had 
most medical aid payments compared to the Western Cape and Kwa-Zulu Natal Province 
accounted for the least medical aid payments. According to the South African Demographics 
and Socio-Economic Status Report employment is a key economic indicator sensitive to 
economic growth. The majority of employed people are employed in the formal economic 
sectors with 9% and 11 % respectively of populations employed in the information sector in 
Gauteng and the Western Cape, Kwa-Zulu Natal has more.   This explains the mode of 
payment trends observed in this study in that the economic status of people in Gauteng is 
higher than that of people from the Western Cape which is also high that that of Kwa-Zulu 
Natal.  Gauteng and the Western Cape according to this report are projected to continue to be 
more economically attractive Provinces for people from other provinces.   
 
The distribution of sales by gender indicates that females account for 59% of all the 
purchasers whilst males accounted for 41%. This is in line with the findings from the 
specialist treatment centre’s study in Cape Town which indicated that of the misused 
analgesics, the codeine-containing OTC medicines were the ones mostly misused and that 
patients using OTC medicines as their primary drug of misuse are more likely to be females 
aged over forty (40) years whilst males over the age of forty (40) use OTC medicines as an 
additional drug of misuse
22
. The distribution of the sales of these products by age in all the 
three provinces over the study period indicates that most purchasers of the over-the-counter 
codeine containing medicines belonged to the age group forty-one (41) to forty-five (45) 
years. The age group accounted for forty-seven (47%) percent of all the purchaser of the 
over-the-counter codeine containing medicine. Findings from an Australian and New Zealand 
study suggest that the misuse and harm from combination codeine analgesics may be a 
growing problem in countries where they are available OTC and that the average age of 
clients addicted to OTC codeine products is 44 years in New Zealand
34
. This is a mature and 
financially stable age group which is likely to be in the formal employment sector or self-
employed and can afford to finance their health needs through medical aid schemes and or 
out of pocket payment. The age group of 60 years and above accounted for 9.4% of the 
purchasers. These are the retired age group which tend to be on chronic medication use as 
well. 
 
The sales trend of the OTC codeine-containing-medicines indicates a steady increase in the 
sale of these products over all three provinces over the study period. When considering the 
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top three OTC codeine-containing medicines with most sales in all three provinces combined 
(Genpayne Capsules, Myprodol Capsules and Mybulen Tablets) they account for seventy-one 
(71%) percent of all the sales of the OTC codeine-containing medicines sold. The two major 
brands that dominate the three provinces’ market for over-the-counter codeine containing 
medicines are Genpayne and Myprodol Capsules, they both contain Codeine Phosphate 
10mg, Ibuprofen 200mg and Paracetamol 250mg and they cost R37.38 and R62.79 per pack 
of 30 tablets respectively. Aspen Pharmacare’s Mybulen Tablets contain Codeine Phosphate 
10mg, Ibuprofen 200mg and Paracetamol 350mg and it cost R42.77 per pack of 30 tablets 
whilst their Mybulen Capsules contain Codeine Phosphate 10mg, Ibuprofen 200mg and 
Paracetamol 250mg and cost R37.38 per pack of 30 tablets. 
 
Genpayne and Myprodol are both Adcock Ingram’s products which have managed to 
maintain their brand equity in the market over the years. Myprodol is the well-known red and 
green capsule that has maintained its leadership in the analgesic market due to their 
continuing growth in sales. Sales force commitment, strong branding and creative advertising 
strategies have contributed to the two brands maintaining their market leadership position in 
the total pharmaceutical market rankings despite the fact that Myprodol is more costly 
compared to Genpayne per pack of 30’s. In all the respective retail pharmacies, the prices of 
these products remain constant because these are Pick n Pay chain stores thus the prices of 
similar medicines are the same. Also, the country regulates the prices of medicines using the 
single exit price system to ensure that medicines are affordable to the general population.  
 
However, top three selling brands do not vary much over the three provinces. The top three 
selling products in the Gauteng Province were Myprodol Capsules thirty (30%) percent, 
Genpayne Capsules nineteen (19%) percent and Mybulen Tablets nine (9%) percent of all the 
sales in the province. In the Western Cape Province the top three sales were Genpayne 
Capsules twenty-eight (28%) percent, Myprodol Capsules twenty-four (24%) percent and 
Mybulen Tablets seventeen point five (17.5%) percent of all sales in the province.  In the 
Kwa-Zulu Natal Province the top three selling products were Genpayne Capsules thirty-seven 
(37%) percent, Myprodol Capsules twenty-nine (29%) percent and Mybulen Tablets fifteen 
(15%) percent of all the sales in the province over the study period. 
 
The findings from the study indicate that the top ten selling brands of OTC codeine 
containing medicines account for eighty-five (85%) percent of all the sales of these products 
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in the Gauteng Province, ninety (90%) percent of all sales of these products in the Western 
Cape Province and ninety-three (93%) percent of the sales of these products in the Kwa-Zulu 
Natal Province. It is worth noting that across all the three provinces the major sales are 
attributed to three main brands namely Genpayne Capsules, Myprodol Capsules and Mybulen 
Tablets. This further illustrates that in Gauteng Province the three products contributed to 
fifty-eight (58%) percent, in Western Cape Province to seventy (70%) percent and in Kwa-
Zulu Natal to eighty-one (81%) percent of the total sales of these OTC codeine containing 
medicines.  McAvoy, Dobbin and Tobin, 2011 concluded that the control of OTC codeine-
containing analgesics in form of making them pharmacist-only medicines was not sufficient 
in limiting their non-medicinal use. An extensive literature review conducted in the United 
Kingdom concluded that there is not much risk when OTC codeine-containing medicines are 
used appropriately to treat occasional pain in the recommended doses; the problem arises 
with the long-term use and the use of high doses that can lead to headaches, dependence and 
potentially severe reactions
53
 and morbidities.  In addition, most people do not consider the 
misuse of these products as inappropriate in comparison to the use of illicit drugs which are 
believed to have a greater potential of causing harm.
54
 
  
5.1 Limitations of the study 
 
The study only examined secondary sales data that was available from the Pick n Pay retail 
pharmacies’ database system at the time of data collection. As a result, not all monthly data 
could be retrieved for the year 2011; only seven (7) months data was available. This was the 
same scenario even with the 2014 data, whereby data ended in June at the time of the data 
collection period. The trend analyses need to take the missing data for some months into 
consideration for comparison purposes. In addition, there were some missing data in the age 
variable due to non-availability of data and thus only available cases were included in the 
analysis. The stand-alone retain pharmacies could not be included in the study due to lack on 
sales data in these pharmacies yet they are more in numbers.  
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5.2 Conclusion and Recommendation 
 
This study has demonstrated that there is a steady increase in the sale of over-the-counter 
codeine containing medicines which may be attributed to the fact that OTC codeine-
containing medicines are relatively easy to purchase compared to prescription only medicines 
that are sold on production of a prescription and illicit drugs. Also, with the growth in the 
awareness of the problems of OTC codeine preparations, regulatory authorities have been 
examining their policies and regulations. In September 2009 the United Kingdom Medicines 
and Healthcare products Regulatory Agency (MHRA) updated its advice on the non-
prescription medicines containing codeine and dihydrocodeine. The Republic of South 
Africa’s Medicines Control Council in February 2015 reduced the strength of codeine and 
dihydrocodeine in OTC codeine containing preparation from 20mg to 10mg and set the 
maximum treatment days to five (5) days. Preparations containing codeine and 
dihydrocodeine above 10mg were rescheduled from schedule 2 to schedule 3. 
 
In Australia, the National Drugs and Poisons Schedule Committee (NDPSC) in May 2010 
reschedules OTC codeine containing medicines to pharmacist-only medicines and reduced 
the pack sizes to thirty (30) tablets.  In New Zealand, the Medical Devices Safety Authority’s 
(MEDSAFE) Medicines Classification Committee in October 2010 also recommended that 
OTC codeine containing medicines be pharmacist-only medicines and the pack size was 
reduced to 30 tablets. In Europe, codeine is a prescription only medicine in Austria, Belgium, 
Croatia, Czech Republic, Finland, Germany, Greece, Italy, Luxembourg, Portugal, Slovakia, 
Spain and Sweden. Codeine is also a prescription only medicine in the USA, Hong Kong, 
Iceland, India, Japan, Maldives, Romania, Russia and the United Arab Emirates  
 
Despite of all of these challenges with OTC codeine containing medicines there is a lot of 
resistance from the pharmaceutical Industry to restrict the sales of OTC codeine products. 
The New Zealand Self-medication Industry Association stated that it, “believes that the needs 
and interests of the vast majority or responsible consumers need to be balanced against the 
risks of harm to a very small number of individuals”37. The South African Pharmaceutical 
Manufacturing Industry and Retail Pharmacy Associations feel that effective self-regulation 
will help preserve the OTC sales of these medicines that would continue benefiting the 
patients thus the establishment of the Codeine Care Initiative by the Community Pharmacist 
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Sector (CPS) and Pharmaceutical Society of South Africa (PSSA) to monitor and audit the 
sale and supply of codeine-containing medicines. However, this ended up becoming 
voluntary and defeating the very reason for its establishment.  
 
In view of this, there is a need for further studies to ascertain if these top three leading brands 
of OTC codeine-containing medicines are being misused or their sales are due to them being 
well marketed. Further, there is a need to ascertain the prevalence of the misuse of OTC 
codeine-containing medicines in South Africa and the evidence to assist in characterising the 
populations most at risk.   This represents urgent aspects where applied research is needed to 
explore the extent of the misuse and the necessary regulation with regards to OTC codeine-
containing medicines in South Africa. The Medical Control Council needs to review the 
Codeine Care Initiative by the Community Pharmacist Sector (CPS) and Pharmaceutical 
Society of South Africa (PSSA) to monitor and audit the sales and supply of codeine-
containing medicines and consider its implementation to all retail pharmacies without an 
option. This will assist in coming up with the secondary data that will inform future studies 
into the use of OTC codeine containing medicines in South Africa. If the monitoring the sales 
of OTC codeine containing medicines does not have an impact on the misuse of these 
products , more drastic measures may need to be considered. 
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Annex 1:  Gantt Chart on timelines for the execution of the Research 
PROJECT 
ACTIVITY 
TIME (Weeks) 
 Aug/Sept 
2015 
Oct/Nov 
2015 
Dec/Jan 
2015/6 
Feb/May 
2016 
Jun/Sept 
2016 
Oct 2016 Nov/Dec 
2016 
 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 
2 3 4 
1 2 3 4 
Submission for 
Assessors  
Approval  
                            
Feedback from 
assessors, 
corrections  and 
resubmission 
                            
Data Collation 
and Data 
Analysis 
                            
Preparation of 
Research 
Report 
                            
Submission of 
Research 
Report 
                            
Correction of 
Research 
Report 
                            
Final 
Submission of 
Research 
Report 
                            
Examiners 
Feedback 
 
                            
Final 
Submission 
for 
Publication 
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Annex 2:  Estimated Budget for the Research 
Activity Description Quantity Unit Price 
(Rand) 
Total (R) 
Stationery Printing Paper 500 x 10 50 500.00 
Stapler 03 x 1 30 90.00 
Folders 50 x 2 10 500.00 
Paper Punch 02 x 1 30 60.00 
Fuel Unleaded Petrol (Litres) 
For travelling purposes 
60 x 5 12 3,600.00 
Communication Email - 100 1,500.00 
Telephone - 1000 5,000.00 
Skype - 100 1,500.00 
Incidentals/Data 
Payment 
 
- - - 5,000.00 
Grand Total 17,750.00 
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Annex 3: List of Products 
 
List of Codeine containing over-the-counter medicines sold by Pick n Pay Retail Pharmacies 
over the study period (Trade Names): 
 
 Trade Name Manufacturer 
 Suspensions & Syrups  
1. Actifed Dry Cough Glaxo Smithkline Consumer 
2. Acutussive Expectorant Syrup Adult Arrow Pharma Subs Actavis 
3. Acutussive Expectorant Syrup Pead Arrow Pharma Subs Actavis 
4. Adco-Kiddipayne Syrup Adcock Generics 
5. Adco-Salterpyn Syrup Adcock Generics 
6. Adco-Tussend Syrup Adco-OTC 
7. Ban Pain Syrup Aspen-Pharmacare 
8. Codeine Phosphate Syrup Medico 
9. Colcaps Syrup Adcock OTC Tail 
10. Docsed Syrup Aspen-Pharmacare 
11. Fludactil Co Linct Syrup Aspen-Pharmacare 
12. Flusin Junior Co Syrup Aspen-Pharmacare 
13. Goldgesic Syrup Pharmachem Pharmaceuticals 
14. Lenazine Forte Syrup Aspen-Pharmacare 
15. Lentogesic Syrup Adcock Restan 
16. Linctifed Expectorant Adult Syrup Glaxo Smithkline Consumer 
17. Mybulen Suspension Aspen-Pharmacare 
18. Myprodol Suspension Adcock Pain 
19. Painagon Syrup Ranbaxy - Be-Tabs 
20. Phensedyl Syrup Zentiva 
21. Pynmed Syrup Cipla-Medpro Pharmaceuticals 
22. Stilpane Syrup Aspen-Pharmacare 
23. Stopayne Syrup Adcock Restan 
24, Tensopyn Syrup Mirren 
25. Tenston Syrup Adcock Pain 
26. Trifen Expectorate Adult Syrup Ranbaxy - Be-Tabs 
27. Trifen Expectorate Paed Syrup Ranbaxy - Be-Tabs 
 Tables & Capsules  
1. Adco-Napacod Tablets Adcock Adco 
2. Adco-Sinal Co Tablets Adcock Adco 
3. Co-Codamol Effeverence Cipla-Medpro Pharmaceuticals 
4. Codeine Phosphate Tablets Aspen-Pharmacare 
5. Dentopain Forte Capsules Sandoz 
6. Dolorol Forte Tablets Aspen-Pharmacare 
7. Empacod Tablets Takeda (Pty) Ltd 
8. Genpayne Tablets Adcock Generics 
9. Ibucod Tablets Aspen-Pharmacare 
10. Ibupain Forte Capsules Sandoz 
11. Mybucod Tablets Aspen-Pharmacare 
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12. Mybulen Tablets & Capsules Aspen-Pharmacare 
13. Myprodol Capsules Adcock Pain 
14. Nurofen Plus Tablets Reckitt Benckiser Pharmac 
15. Sinumax Co Tablets Janssen Pharmaceuticals 
16. Sinutab & Codeine Tablets Johnson And Johnson 
17. Stilpane Capsules Aspen-Pharmacare 
18. Synaleve Capsules Adcock Pain 
 
 
Annex 4: Data Collecting Tool used in the study 
 
 
 
Generic 
Name 
Trade 
Name 
Manufacturer Pack 
Size 
Price Quantity Purchase 
Date 
Mode of 
Payment 
Age of 
Purchaser 
Gender of 
Purchaser 
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
